Surgical Sealants, Adhesives and Hemostats Global Market - Forecast to 2029
Surgical Sealants, Adhesives and Hemostats Global Market - Forecast to 2029
Abstract
Surgical sealants, adhesives, and hemostats (SAH) are the products used to close surgical incisions, post-surgical application, block the passage of fluids through the surface or openings of the wounds, and also to avoid microbial adhesions and infections. Sealants and adhesives are usually considered together as they both adhere to and seal the surgical incisions, while, hemostats are used to achieve hemostasis when the conventional method is ineffective and impractical.
According to IQ4I analysis, the SAH global market is expected to grow at mid-single digit CAGR from 2022 to 2029 to reach $4,366.0 million by 2029. The SAH global market is mainly segmented based on products, applications, end-users, and based on geography. The product market is segmented into sealant, adhesive and hemostat. Among these, the hemostat accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029. The sealants are further segmented based on their origin into natural and synthetic sealants. The synthetic sealant accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029.
The natural sealants are further sub-segmented based on composition into fibrin and albumin sealants. Among them, fibrin accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029. The synthetic sealants are further segmented based on composition into cyanoacrylate, hydrogels, and others. Among them, hydrogels accounted for the largest revenue in 2022 and are expected to grow at mid-single digit CAGR from 2022 to 2029. The adhesive market is segmented into natural and synthetic adhesives, among them; synthetic adhesives accounted for the largest revenue in 2022 and are expected to grow at low-single digit CAGR from 2022 to 2029. The natural adhesives are further sub-segmented based on composition into fibrin and albumin, among them, fibrin adhesive accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029.
The synthetic adhesives are further segmented based on composition into cyanoacrylate and polyurethane. The cyanoacrylate adhesive accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029. Hemostats are classified based on function into mechanical hemostats, active hemostats, flowable hemostats, and fibrin sealants hemostats, among them, the mechanical hemostats accounted for the largest revenue in 2022 and are expected to grow at mid-single digit CAGR from 2022 to 2029. Fibrin sealant hemostat is the fastest growing segment at high-single digit strong CAGR from 2022 to 2029 because it is unique, powerful and effective for localized and diffused bleeding during surgical procedures.
The application market is segmented into Cardiovascular surgery, General Surgery, Orthopedic surgery, Urology, Pulmonology, Neurosurgery, Gynecology, Cosmetic surgery and Others. The general surgery segment accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029, because of high demand for various surgical procedures. Cosmetic surgery is the fastest growing segment at high-single digit CAGR, because of the advancements in treatment regimes available and better cosmetic outcomes.
The end-users market is segmented into hospitals, ambulatory surgical centers, and others. The hospital segment accounted for the largest share in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029, due to an increase in the aging population, increase in surgical procedural volumes, and better patient care services with advanced facilities.
Some of the major players in the SAH market include Baxter International Inc. (U.S.), Johnson & Johnson (Ethicon) (U.S.), Becton, Dickinson & Company (C.R.Bard) (U.S.), Integra Lifescience (U.S.), B.Braun Melsungen AG (Germany), Teleflex (U.S.), Medtronic Plc (Ireland), Artivion Inc. (Cryolife) (U.S.), Advanced Medical Solutions Group Plc (U.K.), Tissium (France), Corza Medical, Inc. (U.S.), Healthium (India), Meril Lifesciences (India), Hemostasis (U.S.), Stryker (U.S.), and Terumo (Japan).
Content
Table of Contents
1 EXECUTIVE SUMMARY 20
2 INTRODUCTION 25
2.1 KEY TAKEAWAYS 25
2.2 SCOPE OF THE REPORT 25
2.3 REPORT DESCRIPTION 26
2.4 MARKETS COVERED 28
2.5 STAKEHOLDERS 29
2.6 RESEARCH METHODOLOGY 30
2.6.1 MARKET SIZE ESTIMATION 31
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 34
2.6.3 SECONDARY SOURCES 35
2.6.4 PRIMARY SOURCES 36
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 36
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 37
2.6.7 ASSUMPTIONS 38
3 MARKET ANALYSIS 40
3.1 INTRODUCTION 40
3.2 MARKET SEGMENTATION 41
3.3 FACTORS INFLUENCING MARKET 43
3.3.1 DRIVERS AND OPPORTUNITIES 44
3.3.1.1 Increasing demand for surgical procedures boosts sah market growth 44
3.3.1.2 The emergence of technically advanced products 45
3.3.1.3 Increasing geriatric population 46
3.3.1.4 Acquisition to open an array of opportunities for the market to flourish 46
3.3.1.5 Acceptance of sah and market expansion in emerging nations 47
3.3.2 RESTRAINTS AND THREATS 48
3.3.2.1 Pitfalls in the usage of sah 48
3.3.2.2 Expensive sah impeding effective penetration in low and
middle-income countries 48
3.3.2.3 Unfavorable reimbursement policies in developing nations 49
3.3.2.4 Stringent regulatory guidelines 50
3.3.2.5 Availability of alternative products 51
3.4 REGULATORY AFFAIRS 51
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 52
3.4.1.1 ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM 52
3.4.1.2 ISO 14644-1 CLEANROOM STANDARDS 52
3.4.1.3 ISO 13485 MEDICAL DEVICES 52
3.4.1.4 ISO 10993 BIOLOGICAL EVALUATION OF MEDICAL DEVICES 53
3.4.2 ASTM INTERNATIONAL STANDARDS 53
3.4.3 U.S. 53
3.4.4 CANADA 56
3.4.5 EUROPE 56
3.4.6 JAPAN 57
3.4.7 CHINA 58
3.4.8 INDIA 60
3.5 TECHNOLOGICAL ADVANCEMENTS 62
3.5.1 BIOGLUE 62
3.5.2 BIOINSPIRED GLUE FROM BARNACLES 62
3.5.3 SNAKE-DERIVED SUPER GLUE 62
3.5.4 ALGA MIMETIC TECHNOLOGY 62
3.5.5 A POLYMER PATCH FOR THE ABDOMINAL CAVITY 63
3.6 CLINICAL TRIALS 63
3.7 FUNDING SCENARIO 66
3.8 PORTER’S FIVE FORCE ANALYSIS 67
3.8.1 THREAT OF NEW ENTRANTS 68
3.8.2 THREAT OF SUBSTITUTES 69
3.8.3 BARGAINING POWER OF SUPPLIERS 70
3.8.4 BARGAINING POWER OF BUYERS 70
3.8.5 RIVALRY AMONG EXISTING COMPETITORS 71
3.9 SUPPLY CHAIN ANALYSIS 72
3.10 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 75
3.10.1 SAH GLOBAL MARKET SHARE ANALYSIS 75
3.10.2 SURGICAL SEALANTS GLOBAL MARKET SHARE ANALYSIS 78
3.10.3 SURGICAL ADHESIVES GLOBAL MARKET SHARE ANALYSIS 81
3.10.4 HEMOSTATS GLOBAL MARKET SHARE ANALYSIS 83
3.11 SAH COMPANY MATRIX 85
4 SURGICAL SEALANTS, ADHESIVES AND HEMOSTATS GLOBAL MARKET, BASED ON PRODUCT 90
4.1 INTRODUCTION 90
4.2 SEALANTS 93
4.2.1 NATURAL SEALANTS 97
4.2.1.1 Fibrin natural sealants 102
4.2.1.2 Albumin natural sealants 105
4.2.2 SYNTHETIC SEALANTS 108
4.2.2.1 Cyanoacrylate 112
4.2.2.2 Hydrogels 113
4.2.2.3 Others 115
4.3 ADHESIVES 117
4.3.1 NATURAL ADHESIVES 120
4.3.1.1 Fibrin natural adhesives 123
4.3.1.2 Albumin natural adhesives 125
4.3.2 SYNTHETIC ADHESIVES 126
4.3.2.1 Cyanoacrylate 131
4.3.2.2 Polyurethane 132
4.4 HEMOSTATS 134
4.4.1 MECHANICAL HEMOSTATS 138
4.4.2 ACTIVE HEMOSTATS 141
4.4.3 FLOWABLE HEMOSTATS 143
4.4.4 FIBRIN SEALANT HEMOSTATS 145
5 SURGICAL SEALANTS, ADHESIVES AND HEMOSTATS GLOBAL MARKET, BASED ON APPLICATION 147
5.1 INTRODUCTION 147
5.2 CARDIOVASCULAR SURGERY 150
5.3 GENERAL SURGERY 151
5.4 ORTHOPEDIC SURGERY 153
5.5 UROLOGY 155
5.6 PULMONOLOGY 157
5.7 NEUROSURGERY 159
5.8 GYNECOLOGY 161
5.9 COSMETIC SURGERY 163
5.10 OTHERS 165
6 SURGICAL SEALANTS, ADHESIVES AND HEMOSTATS GLOBAL MARKET, BASED ON END-USERS 167
6.1 INTRODUCTION 167
6.2 HOSPITALS 170
6.3 AMBULATORY SURGICAL CENTERS 172
6.4 OTHERS 174
7 SURGICAL SEALANTS, ADHESIVES AND HEMOSTATS GLOBAL MARKET, BASED ON REGION 176
7.1 INTRODUCTION 176
7.2 NORTH AMERICA 180
7.2.1 THE U.S. 204
7.2.2 REST OF NORTH AMERICA 207
7.3 EUROPE 211
7.3.1 GERMANY 236
7.3.2 THE U.K. 239
7.3.3 FRANCE 242
7.3.4 REST OF E.U. 245
7.4 APAC 248
7.4.1 JAPAN 271
7.4.2 CHINA 275
7.4.3 INDIA 278
7.4.4 REST OF APAC 280
7.5 ROW 284
7.5.1 BRAZIL 308
7.5.2 REST OF LATAM 311
7.5.3 MIDDLE EAST AND OTHERS 314
8 MAJOR COMPANIES 317
8.1 ADVANCED MEDICAL SOLUTIONS 317
8.1.1 OVERVIEW 317
8.1.2 FINANCIALS 318
8.1.3 PRODUCT PORTFOLIO 321
8.1.4 KEY DEVELOPMENTS 321
8.1.5 BUSINESS STRATEGY 322
8.1.6 SWOT ANALYSIS 322
8.2 ARTIVION 323
8.2.1 OVERVIEW 323
8.2.2 FINANCIALS 324
8.2.3 PRODUCT PORTFOLIO 327
8.2.4 KEY DEVELOPMENTS 327
8.2.5 BUSINESS STRATEGY 327
8.2.6 SWOT ANALYSIS 328
8.3 BAXTER INTERNATIONAL, INC 329
8.3.1 OVERVIEW 329
8.3.2 FINANCIALS 330
8.3.3 PRODUCT PORTFOLIO 332
8.3.4 KEY DEVELOPMENTS 333
8.3.5 BUSINESS STRATEGY 333
8.3.6 SWOT ANALYSIS 334
8.4 B.BRAUN MELSUNGEN AG 335
8.4.1 OVERVIEW 335
8.4.2 FINANCIALS 336
8.4.3 PRODUCT PORTFOLIO 339
8.4.4 KEY DEVELOPMENTS 339
8.4.5 BUSINESS STRATEGY 339
8.4.6 SWOT ANALYSIS 340
8.5 BECTON, DICKINSON AND COMPANY (C.R.BARD INC.) 341
8.5.1 OVERVIEW 341
8.5.2 FINANCIALS 342
8.5.3 PRODUCT PORTFOLIO 344
8.5.4 KEY DEVELOPMENTS 345
8.5.5 BUSINESS STRATEGY 345
8.5.6 SWOT ANALYSIS 346
8.6 CORZA MEDICAL 347
8.6.1 OVERVIEW 347
8.6.2 FINANCIALS 347
8.6.3 PRODUCT PORTFOLIO 347
8.6.4 KEY DEVELOPMENTS 348
8.6.5 BUSINESS STRATEGY 348
8.6.6 SWOT ANALYSIS 349
8.7 INTEGRA LIFESCIENCE 350
8.7.1 OVERVIEW 350
8.7.2 FINANCIALS 351
8.7.3 PRODUCT PORTFOLIO 354
8.7.4 KEY DEVELOPMENTS 354
8.7.5 BUSINESS STRATEGY 355
8.7.6 SWOT ANALYSIS 355
8.8 JOHNSON & JOHNSON (ETHICON) 356
8.8.1 OVERVIEW 356
8.8.2 FINANCIALS 357
8.8.3 PRODUCT PORTFOLIO 360
8.8.4 KEY DEVELOPMENTS 361
8.8.5 BUSINESS STRATEGY 361
8.8.6 SWOT ANALYSIS 362
8.9 MEDTRONIC, PLC 363
8.9.1 OVERVIEW 363
8.9.2 FINANCIALS 364
8.9.3 PRODUCT PORTFOLIO 367
8.9.4 KEY DEVELOPMENTS 367
8.9.5 BUSINESS STRATEGY 367
8.9.6 SWOT ANALYSIS 368
8.10 TELEFLEX 369
8.10.1 OVERVIEW 369
8.10.2 FINANCIALS 370
8.10.3 PRODUCT PORTFOLIO 372
8.10.4 KEY DEVELOPMENTS 373
8.10.5 BUSINESS STRATEGY 373
8.10.6 SWOT ANALYSIS 374
According to IQ4I analysis, the SAH global market is expected to grow at mid-single digit CAGR from 2022 to 2029 to reach $4,366.0 million by 2029. The SAH global market is mainly segmented based on products, applications, end-users, and based on geography. The product market is segmented into sealant, adhesive and hemostat. Among these, the hemostat accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029. The sealants are further segmented based on their origin into natural and synthetic sealants. The synthetic sealant accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029.
The natural sealants are further sub-segmented based on composition into fibrin and albumin sealants. Among them, fibrin accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029. The synthetic sealants are further segmented based on composition into cyanoacrylate, hydrogels, and others. Among them, hydrogels accounted for the largest revenue in 2022 and are expected to grow at mid-single digit CAGR from 2022 to 2029. The adhesive market is segmented into natural and synthetic adhesives, among them; synthetic adhesives accounted for the largest revenue in 2022 and are expected to grow at low-single digit CAGR from 2022 to 2029. The natural adhesives are further sub-segmented based on composition into fibrin and albumin, among them, fibrin adhesive accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029.
The synthetic adhesives are further segmented based on composition into cyanoacrylate and polyurethane. The cyanoacrylate adhesive accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029. Hemostats are classified based on function into mechanical hemostats, active hemostats, flowable hemostats, and fibrin sealants hemostats, among them, the mechanical hemostats accounted for the largest revenue in 2022 and are expected to grow at mid-single digit CAGR from 2022 to 2029. Fibrin sealant hemostat is the fastest growing segment at high-single digit strong CAGR from 2022 to 2029 because it is unique, powerful and effective for localized and diffused bleeding during surgical procedures.
The application market is segmented into Cardiovascular surgery, General Surgery, Orthopedic surgery, Urology, Pulmonology, Neurosurgery, Gynecology, Cosmetic surgery and Others. The general surgery segment accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029, because of high demand for various surgical procedures. Cosmetic surgery is the fastest growing segment at high-single digit CAGR, because of the advancements in treatment regimes available and better cosmetic outcomes.
The end-users market is segmented into hospitals, ambulatory surgical centers, and others. The hospital segment accounted for the largest share in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029, due to an increase in the aging population, increase in surgical procedural volumes, and better patient care services with advanced facilities.
Some of the major players in the SAH market include Baxter International Inc. (U.S.), Johnson & Johnson (Ethicon) (U.S.), Becton, Dickinson & Company (C.R.Bard) (U.S.), Integra Lifescience (U.S.), B.Braun Melsungen AG (Germany), Teleflex (U.S.), Medtronic Plc (Ireland), Artivion Inc. (Cryolife) (U.S.), Advanced Medical Solutions Group Plc (U.K.), Tissium (France), Corza Medical, Inc. (U.S.), Healthium (India), Meril Lifesciences (India), Hemostasis (U.S.), Stryker (U.S.), and Terumo (Japan).
1 EXECUTIVE SUMMARY 20
2 INTRODUCTION 25
2.1 KEY TAKEAWAYS 25
2.2 SCOPE OF THE REPORT 25
2.3 REPORT DESCRIPTION 26
2.4 MARKETS COVERED 28
2.5 STAKEHOLDERS 29
2.6 RESEARCH METHODOLOGY 30
2.6.1 MARKET SIZE ESTIMATION 31
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 34
2.6.3 SECONDARY SOURCES 35
2.6.4 PRIMARY SOURCES 36
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 36
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 37
2.6.7 ASSUMPTIONS 38
3 MARKET ANALYSIS 40
3.1 INTRODUCTION 40
3.2 MARKET SEGMENTATION 41
3.3 FACTORS INFLUENCING MARKET 43
3.3.1 DRIVERS AND OPPORTUNITIES 44
3.3.1.1 Increasing demand for surgical procedures boosts sah market growth 44
3.3.1.2 The emergence of technically advanced products 45
3.3.1.3 Increasing geriatric population 46
3.3.1.4 Acquisition to open an array of opportunities for the market to flourish 46
3.3.1.5 Acceptance of sah and market expansion in emerging nations 47
3.3.2 RESTRAINTS AND THREATS 48
3.3.2.1 Pitfalls in the usage of sah 48
3.3.2.2 Expensive sah impeding effective penetration in low and
middle-income countries 48
3.3.2.3 Unfavorable reimbursement policies in developing nations 49
3.3.2.4 Stringent regulatory guidelines 50
3.3.2.5 Availability of alternative products 51
3.4 REGULATORY AFFAIRS 51
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 52
3.4.1.1 ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM 52
3.4.1.2 ISO 14644-1 CLEANROOM STANDARDS 52
3.4.1.3 ISO 13485 MEDICAL DEVICES 52
3.4.1.4 ISO 10993 BIOLOGICAL EVALUATION OF MEDICAL DEVICES 53
3.4.2 ASTM INTERNATIONAL STANDARDS 53
3.4.3 U.S. 53
3.4.4 CANADA 56
3.4.5 EUROPE 56
3.4.6 JAPAN 57
3.4.7 CHINA 58
3.4.8 INDIA 60
3.5 TECHNOLOGICAL ADVANCEMENTS 62
3.5.1 BIOGLUE 62
3.5.2 BIOINSPIRED GLUE FROM BARNACLES 62
3.5.3 SNAKE-DERIVED SUPER GLUE 62
3.5.4 ALGA MIMETIC TECHNOLOGY 62
3.5.5 A POLYMER PATCH FOR THE ABDOMINAL CAVITY 63
3.6 CLINICAL TRIALS 63
3.7 FUNDING SCENARIO 66
3.8 PORTER’S FIVE FORCE ANALYSIS 67
3.8.1 THREAT OF NEW ENTRANTS 68
3.8.2 THREAT OF SUBSTITUTES 69
3.8.3 BARGAINING POWER OF SUPPLIERS 70
3.8.4 BARGAINING POWER OF BUYERS 70
3.8.5 RIVALRY AMONG EXISTING COMPETITORS 71
3.9 SUPPLY CHAIN ANALYSIS 72
3.10 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 75
3.10.1 SAH GLOBAL MARKET SHARE ANALYSIS 75
3.10.2 SURGICAL SEALANTS GLOBAL MARKET SHARE ANALYSIS 78
3.10.3 SURGICAL ADHESIVES GLOBAL MARKET SHARE ANALYSIS 81
3.10.4 HEMOSTATS GLOBAL MARKET SHARE ANALYSIS 83
3.11 SAH COMPANY MATRIX 85
4 SURGICAL SEALANTS, ADHESIVES AND HEMOSTATS GLOBAL MARKET, BASED ON PRODUCT 90
4.1 INTRODUCTION 90
4.2 SEALANTS 93
4.2.1 NATURAL SEALANTS 97
4.2.1.1 Fibrin natural sealants 102
4.2.1.2 Albumin natural sealants 105
4.2.2 SYNTHETIC SEALANTS 108
4.2.2.1 Cyanoacrylate 112
4.2.2.2 Hydrogels 113
4.2.2.3 Others 115
4.3 ADHESIVES 117
4.3.1 NATURAL ADHESIVES 120
4.3.1.1 Fibrin natural adhesives 123
4.3.1.2 Albumin natural adhesives 125
4.3.2 SYNTHETIC ADHESIVES 126
4.3.2.1 Cyanoacrylate 131
4.3.2.2 Polyurethane 132
4.4 HEMOSTATS 134
4.4.1 MECHANICAL HEMOSTATS 138
4.4.2 ACTIVE HEMOSTATS 141
4.4.3 FLOWABLE HEMOSTATS 143
4.4.4 FIBRIN SEALANT HEMOSTATS 145
5 SURGICAL SEALANTS, ADHESIVES AND HEMOSTATS GLOBAL MARKET, BASED ON APPLICATION 147
5.1 INTRODUCTION 147
5.2 CARDIOVASCULAR SURGERY 150
5.3 GENERAL SURGERY 151
5.4 ORTHOPEDIC SURGERY 153
5.5 UROLOGY 155
5.6 PULMONOLOGY 157
5.7 NEUROSURGERY 159
5.8 GYNECOLOGY 161
5.9 COSMETIC SURGERY 163
5.10 OTHERS 165
6 SURGICAL SEALANTS, ADHESIVES AND HEMOSTATS GLOBAL MARKET, BASED ON END-USERS 167
6.1 INTRODUCTION 167
6.2 HOSPITALS 170
6.3 AMBULATORY SURGICAL CENTERS 172
6.4 OTHERS 174
7 SURGICAL SEALANTS, ADHESIVES AND HEMOSTATS GLOBAL MARKET, BASED ON REGION 176
7.1 INTRODUCTION 176
7.2 NORTH AMERICA 180
7.2.1 THE U.S. 204
7.2.2 REST OF NORTH AMERICA 207
7.3 EUROPE 211
7.3.1 GERMANY 236
7.3.2 THE U.K. 239
7.3.3 FRANCE 242
7.3.4 REST OF E.U. 245
7.4 APAC 248
7.4.1 JAPAN 271
7.4.2 CHINA 275
7.4.3 INDIA 278
7.4.4 REST OF APAC 280
7.5 ROW 284
7.5.1 BRAZIL 308
7.5.2 REST OF LATAM 311
7.5.3 MIDDLE EAST AND OTHERS 314
8 MAJOR COMPANIES 317
8.1 ADVANCED MEDICAL SOLUTIONS 317
8.1.1 OVERVIEW 317
8.1.2 FINANCIALS 318
8.1.3 PRODUCT PORTFOLIO 321
8.1.4 KEY DEVELOPMENTS 321
8.1.5 BUSINESS STRATEGY 322
8.1.6 SWOT ANALYSIS 322
8.2 ARTIVION 323
8.2.1 OVERVIEW 323
8.2.2 FINANCIALS 324
8.2.3 PRODUCT PORTFOLIO 327
8.2.4 KEY DEVELOPMENTS 327
8.2.5 BUSINESS STRATEGY 327
8.2.6 SWOT ANALYSIS 328
8.3 BAXTER INTERNATIONAL, INC 329
8.3.1 OVERVIEW 329
8.3.2 FINANCIALS 330
8.3.3 PRODUCT PORTFOLIO 332
8.3.4 KEY DEVELOPMENTS 333
8.3.5 BUSINESS STRATEGY 333
8.3.6 SWOT ANALYSIS 334
8.4 B.BRAUN MELSUNGEN AG 335
8.4.1 OVERVIEW 335
8.4.2 FINANCIALS 336
8.4.3 PRODUCT PORTFOLIO 339
8.4.4 KEY DEVELOPMENTS 339
8.4.5 BUSINESS STRATEGY 339
8.4.6 SWOT ANALYSIS 340
8.5 BECTON, DICKINSON AND COMPANY (C.R.BARD INC.) 341
8.5.1 OVERVIEW 341
8.5.2 FINANCIALS 342
8.5.3 PRODUCT PORTFOLIO 344
8.5.4 KEY DEVELOPMENTS 345
8.5.5 BUSINESS STRATEGY 345
8.5.6 SWOT ANALYSIS 346
8.6 CORZA MEDICAL 347
8.6.1 OVERVIEW 347
8.6.2 FINANCIALS 347
8.6.3 PRODUCT PORTFOLIO 347
8.6.4 KEY DEVELOPMENTS 348
8.6.5 BUSINESS STRATEGY 348
8.6.6 SWOT ANALYSIS 349
8.7 INTEGRA LIFESCIENCE 350
8.7.1 OVERVIEW 350
8.7.2 FINANCIALS 351
8.7.3 PRODUCT PORTFOLIO 354
8.7.4 KEY DEVELOPMENTS 354
8.7.5 BUSINESS STRATEGY 355
8.7.6 SWOT ANALYSIS 355
8.8 JOHNSON & JOHNSON (ETHICON) 356
8.8.1 OVERVIEW 356
8.8.2 FINANCIALS 357
8.8.3 PRODUCT PORTFOLIO 360
8.8.4 KEY DEVELOPMENTS 361
8.8.5 BUSINESS STRATEGY 361
8.8.6 SWOT ANALYSIS 362
8.9 MEDTRONIC, PLC 363
8.9.1 OVERVIEW 363
8.9.2 FINANCIALS 364
8.9.3 PRODUCT PORTFOLIO 367
8.9.4 KEY DEVELOPMENTS 367
8.9.5 BUSINESS STRATEGY 367
8.9.6 SWOT ANALYSIS 368
8.10 TELEFLEX 369
8.10.1 OVERVIEW 369
8.10.2 FINANCIALS 370
8.10.3 PRODUCT PORTFOLIO 372
8.10.4 KEY DEVELOPMENTS 373
8.10.5 BUSINESS STRATEGY 373
8.10.6 SWOT ANALYSIS 374
Related Report
